HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
-
Correspondence: Ralf Landgraf rlandgraf@mednet.ucla.edu
University of California Los Angeles, Department of Medicine, Hematology-Oncology and Biological Chemistry, Molecular Biology Institute, Los Angeles, California 90095-1678, USA
Breast Cancer Research 2007, 9:202 doi:10.1186/bcr1633
Published: 22 January 2007Abstract
EGFR-type receptor tyrosine kinases achieve a broad spectrum of cellular responses by utilizing a set of structurally conserved building blocks. Based on available crystal structures and biochemical information, significant new insights have emerged into modes of receptor control, its deregulation in cancer, and the nuances that differentiate the four human receptors. This review gives an overview of current models of the control of receptor activity with a special emphasis on HER2 and HER3.